| scholarly article | Q13442814 |
| P50 | author | Kenneth C. Anderson | Q28421846 |
| P2093 | author name string | Teru Hideshima | |
| Yu-Tzu Tai | |||
| Noopur Raje | |||
| Kohichi Takada | |||
| Gullu Gorgun | |||
| Yunyu Zhang | |||
| Moshe Gatt | |||
| Daniel E Carrasco | |||
| Daniel R Carrasco | |||
| Jui Dutta-Simmons | |||
| Mala Mani | |||
| Anthony G Letai | |||
| Nicole E Carlson | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 2699-2708 | |
| P577 | publication date | 2009-08-03 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression | |
| P478 | volume | 114 |
| Q33873840 | A genome-wide siRNA screen identifies novel phospho-enzymes affecting Wnt/β-catenin signaling in mouse embryonic stem cells |
| Q33944281 | A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma |
| Q91636854 | Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options |
| Q37589988 | Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins. |
| Q39405526 | Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells |
| Q54979116 | Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer. |
| Q38223271 | Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013). |
| Q33618929 | Aurora kinases: novel therapy targets in cancers |
| Q90087524 | Bioinformatics analysis identifies hub genes and pathways in nasopharyngeal carcinoma |
| Q39115623 | Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships |
| Q38459874 | Effects of β-catenin on differentially expressed genes in multiple myeloma |
| Q38730550 | Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma |
| Q36706862 | Expression of aurora kinase A correlates with the Wnt-modulator RACGAP1 in gastric cancer |
| Q38169258 | Fact or fiction--identifying the elusive multiple myeloma stem cell |
| Q52691304 | Formin 2 Regulates Lysosomal Degradation of Wnt-Associated β-Catenin in Neural Progenitors. |
| Q28477988 | Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines |
| Q62559475 | Ghrelin Upregulates Oncogenic Aurora A to Promote Renal Cell Carcinoma Invasion |
| Q64256812 | Identification of key genes and pathways in hepatocellular carcinoma: A preliminary bioinformatics analysis |
| Q48959453 | Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. |
| Q50942246 | Loss of FAM46C Promotes Cell Survival in Myeloma. |
| Q58102399 | Molecular characterization of Wnt pathway and function of β-catenin overexpression in medulloblastoma cell lines |
| Q64085662 | Molecular pathogenic pathways in extranodal NK/T cell lymphoma |
| Q49919956 | Multiple oncogenic roles of nuclear beta-catenin. |
| Q38949755 | N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation |
| Q42815166 | Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro |
| Q37707383 | Novel therapeutic targets for multiple myeloma |
| Q33768466 | Osteoblastogenesis and tumor growth in myeloma |
| Q55056081 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. |
| Q33412196 | Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia |
| Q39029761 | Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway |
| Q28537857 | Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma |
| Q41988752 | RNF4-Dependent Oncogene Activation by Protein Stabilization. |
| Q37789052 | Role of Wnt canonical pathway in hematological malignancies |
| Q37007610 | TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity |
| Q24632740 | Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling |
| Q36164893 | Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism |
| Q60019698 | The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation |
| Q38940139 | The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences |
| Q34020937 | Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4 |
| Q34169968 | Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma |
| Q61814317 | Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders |
| Q50523190 | Two classes of short intraflagellar transport train with different 3D structures are present in Chlamydomonas flagella. |
| Q47107700 | VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. |
| Q28485498 | WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling |
| Q38908764 | WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited |
| Q37433642 | Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target |
| Q54956715 | Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. |
| Q39799555 | Wnt/ß-catenin: a new therapeutic approach to acute myeloid leukemia |
| Q38360083 | miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway |
| Q40094733 | β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome-aggresome-autophagosome-lysosome pathway. |
| Q35124210 | β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma |
Search more.